Thomas E. Witzig, M.D.

Location: Minnesota

Primary Appointment
Hematology
Joint Appointment
Laboratory Medicine and Pathology
Academic Rank
Professor of Medicine

Summary

Dr. Witzig has research interests in Hodgkin and non-Hodgkin lymphoma, multiple myeloma, and chronic lymphocytic leukemia. His laboratory research centers around the study of new agents that interfere with signal transduction pathways in lymphoma and myeloma cells. This has led to clinical trials of new agents that focus on the PI3 kinase signal transduction pathway. These agents include temsirolimus and everolimus. He has also been involved in some of the first studies of lenalidomide for lymphoma. He has a long-standing interest in radioimmunotherapy and is conducting new research that combines immunomodulatory agents with Zevalin radioimmunotherapy.

Recent publications

See my publications

Education

Fellowship – Medical Onocology
Mayo Graduate School of Medicine, College of Medicine, Mayo Clinic

Research Fellowship – Clinical Hematology
Mayo Graduate School of Medicine, College of Medicine, Mayo Clinic

Residency – Clinical Hematology
Mayo Graduate School of Medicine, College of Medicine, Mayo Clinic

Residency – Department of Internal Medicine
University of Iowa Hospitals and Clinics

M.D. – Medicine
University of Illinois College of Medicine

B.S. – Biology
Illinois State University

Areas of Research
Epidemiology of Lymphoma and Leukemia Research Program

Appointments | Contact Us | Give to Mayo Clinic | Search

LEGAL RESTRICTIONS AND TERMS OF USE APPLICABLE TO THIS SITE